HK1220904A1 - 聚合物膠束醫藥組合物 - Google Patents

聚合物膠束醫藥組合物

Info

Publication number
HK1220904A1
HK1220904A1 HK16109033.2A HK16109033A HK1220904A1 HK 1220904 A1 HK1220904 A1 HK 1220904A1 HK 16109033 A HK16109033 A HK 16109033A HK 1220904 A1 HK1220904 A1 HK 1220904A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
polymeric micelle
micelle pharmaceutical
polymeric
composition
Prior art date
Application number
HK16109033.2A
Other languages
English (en)
Inventor
加藤泰己
原田充訓
田中亮佑
Original Assignee
Nanocarrier Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanocarrier Co Ltd filed Critical Nanocarrier Co Ltd
Publication of HK1220904A1 publication Critical patent/HK1220904A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
HK16109033.2A 2013-05-17 2016-07-28 聚合物膠束醫藥組合物 HK1220904A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013105465 2013-05-17
PCT/JP2014/063020 WO2014185504A1 (ja) 2013-05-17 2014-05-16 ポリマーミセル医薬組成物

Publications (1)

Publication Number Publication Date
HK1220904A1 true HK1220904A1 (zh) 2017-05-19

Family

ID=51898479

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16105898.4A HK1217905A1 (zh) 2013-05-17 2016-05-24 聚合物膠束醫藥組合物
HK16109033.2A HK1220904A1 (zh) 2013-05-17 2016-07-28 聚合物膠束醫藥組合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16105898.4A HK1217905A1 (zh) 2013-05-17 2016-05-24 聚合物膠束醫藥組合物

Country Status (14)

Country Link
US (1) US20160114058A1 (zh)
EP (1) EP2997979A4 (zh)
JP (1) JP5692887B1 (zh)
KR (1) KR20160007529A (zh)
CN (1) CN105377302B (zh)
AU (1) AU2014266254B2 (zh)
BR (1) BR112015028414A2 (zh)
CA (1) CA2911495A1 (zh)
HK (2) HK1217905A1 (zh)
MX (1) MX2015015334A (zh)
RU (1) RU2015153913A (zh)
SG (1) SG11201509460UA (zh)
TW (1) TWI632922B (zh)
WO (1) WO2014185504A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701740B2 (en) 2011-04-01 2017-07-11 Yale University Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
EP3141243B1 (en) 2014-05-08 2020-07-08 The University of Tokyo Pharmaceutical composition
WO2017170846A1 (ja) * 2016-03-30 2017-10-05 ナノキャリア株式会社 ポリマーミセル医薬組成物
CA3027960C (en) 2016-06-15 2022-06-14 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US20190330317A1 (en) 2016-06-15 2019-10-31 Yale University Anti-guanosine antibody as a molecular delivery vehicle
WO2018025699A1 (ja) * 2016-08-02 2018-02-08 日本化薬株式会社 アクティブターゲティング型高分子誘導体、その高分子誘導体を含む組成物、及びそれらの用途
WO2023056450A1 (en) 2021-09-30 2023-04-06 Yale University Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT852243E (pt) 1995-04-14 2003-03-31 Kazunori Kataoka Polioxido de etileno tendo um residuo de um sacarideo numa das extremidades e um grupo funcional diferente na outra extremidade e processo para a producao do mesmo
CN1085987C (zh) 1995-04-19 2002-06-05 片冈一则 杂远螯嵌段共聚物及其制备方法
EP0844269B1 (en) 1995-08-10 2002-10-23 Kazunori Kataoka Block copolymer having functional groups at both ends
CA2724821A1 (en) * 2008-05-23 2009-11-26 Nanocarrier Co., Ltd. Polymer derivative of docetaxel, method of preparing the same and uses thereof
EP2133433A1 (en) * 2008-06-09 2009-12-16 Centre Georges François Leclerc A method for predicting responsiveness to a treatment with an anti-HER2 antibody
JP4538666B2 (ja) 2008-07-29 2010-09-08 ナノキャリア株式会社 薬物内包アクティブターゲット型高分子ミセル、医薬組成物
JP4829351B2 (ja) * 2010-02-05 2011-12-07 ナノキャリア株式会社 易崩壊型ポリマーミセル組成物

Also Published As

Publication number Publication date
TWI632922B (zh) 2018-08-21
AU2014266254B2 (en) 2018-12-13
CN105377302B (zh) 2018-05-11
EP2997979A1 (en) 2016-03-23
TW201524533A (zh) 2015-07-01
HK1217905A1 (zh) 2017-01-27
KR20160007529A (ko) 2016-01-20
US20160114058A1 (en) 2016-04-28
BR112015028414A2 (pt) 2017-07-25
CN105377302A (zh) 2016-03-02
JP5692887B1 (ja) 2015-04-01
RU2015153913A3 (zh) 2018-04-25
CA2911495A1 (en) 2014-11-20
SG11201509460UA (en) 2015-12-30
JPWO2014185504A1 (ja) 2017-02-23
WO2014185504A1 (ja) 2014-11-20
MX2015015334A (es) 2016-03-04
WO2014185504A8 (ja) 2015-01-22
AU2014266254A1 (en) 2015-12-03
EP2997979A4 (en) 2016-10-12
RU2015153913A (ru) 2017-06-22

Similar Documents

Publication Publication Date Title
IL288961A (en) Pharmaceutical preparations
RS59756B1 (sr) Kombinovana farmaceutska kompozicija
PL2943181T3 (pl) Kompozycje farmaceutyczne
PL3043778T3 (pl) Kompozycje farmaceutyczne zawierające refametinib
HK1220904A1 (zh) 聚合物膠束醫藥組合物
ZA201408333B (en) Pharmaceutical compositions
HK1213182A1 (zh) 外用藥物組合物
EP2990038A4 (en) SOLID PHARMACEUTICAL COMPOSITION
SG11201601477VA (en) Pharmaceutical composition
HK1219691A1 (zh) 醫藥組成物及其用途
AP2015008894A0 (en) Pharmaceutical preparation
ZA201601645B (en) Bendamustine pharmaceutical compositions
HRP20171888T1 (hr) Farmaceutski pripravci
HUP1300496A2 (hu) Stabil kombinációs gyógyszerkészítmény
HK1220143A1 (zh) 藥物組合物
GB201304699D0 (en) Pharmaceutical compositions
EP2992890A4 (en) Pharmaceutical composition
IL244316A0 (en) A new composition of a drug
GB201321497D0 (en) Pharmaceutical compositions
GB201312851D0 (en) Pharmaceutical compositions
GB201304625D0 (en) New pharmaceutical composition
AU2013903813A0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230511